Management pattern for patients with osteoarthritis treated with traditional nonsteroidal anti-inflammatory drugs in Spain prior to introduction of Coxibs

Current Medical Research and Opinion

Volumn 19, Issue 4, 2003, Pages 278-287

  Arboleya, Luis R ^a   De la Figuera, Enrique ^b   García, María Soledad ^c   Aragón, Belén ^c  

^a HOSPITAL DE CABUEÑES   (Spain)

^b CENTRO DE SALUD DELICIAS SUR   (Spain)

^c Chiltern International ^*  (Spain)

Author keywords

Dissatisfaction; GI toxicity; Lack of efficacy; NSAIDs; Osteoarthritis; Pain relief

Indexed keywords

ACECLOFENAC; ACEXAMATE ZINC; ALMAGATE; ANALGESIC AGENT; ANTACID AGENT; CAPSAICIN; CODEINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; GLUCOSAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYALURONIC ACID; IBUPROFEN; INDOMETACIN; MELOXICAM; MISOPROSTOL; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PIROXICAM; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; TENOXICAM; UNINDEXED DRUG; ZINC DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG INDICATION; DRUG UTILIZATION; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; ESOPHAGITIS; FEMALE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; KNEE OSTEOARTHRITIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MELENA; NAUSEA AND VOMITING; OBSERVATION; OSTEOARTHRITIS; OUTCOMES RESEARCH; PAIN ASSESSMENT; PATIENT SATISFACTION; PRESCRIPTION; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SKELETON RADIOGRAPHY; SPAIN; STOMACH PROTECTION; STOMACH ULCER; SYMPTOM; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; RETROSPECTIVE STUDIES; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0038343118     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125001712     Document Type: Article

References (33)

1. Carmona L. Artrosis. In: Sociedad Española de Reumatología, editores. Estudio EPISER. Prevalencia e impacto de las enfermedades reumáticas en la población adulta española (Spanish). Madrid, 2001:61-75
2. Arboleya LR, de la Figuera E, Soledad García M, Aragón B and the VICOXX Study Group. Experience of refocoxib in patients with osteoarthritis previously treated with traditional nonsteroidal anti-inflammatory drugs in Spain. Curr Med Res Opin 2003;19(4):288-297
3. Espallargues M, Alonso J, Ruigomez Anto JM. Alteraciones osteoarticulares en la vejez: aproximación a su impacto poblacional (Spanish). Med Clin (Barc) 1996;106:617-18
4. Adams EH, Hunter TS, Williams T. New options in the treatment of arthritis. J Managed Care Pharm 1999;5:414-19
5. Moreno Brea MR, Morales Serna JC, Ignacio García JM. Evolución del consumo de antiinflamatorios no esteroideos en el distrito de atención primaria de Jerez (Cádiz) (Spanish). Aten Farm 1999;1:345-56
6. Alonso Alonso C, Alonso Calo L, Candas Villar A, Fernández C, Hevia Rodríguez E, Turiel Lobo P. Estudio de utilización de antiinflamatorios no esteroideos (Spanish). Aten Primaria 1996;18 (Suppl 1):360
7. IMS. International Marketing Services, 2001
8. Henry D, Lim L L-Y, García Rodríguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6
9. García Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998;158:33-9
10. Clinard F, Bardou M, Sgro C, Lefevre N, Raphael F, Paille F, et al. Non-steroidal anti-inflammatory and cytoprotective drug coprescription in general practice. Eur J Clin Pharmacol 2001;57:737-43
11. Hawkey CJ, Cullen DJE, Pearson G, Holmes S, Doherty M, Wilson JV, et al. Pharmacoepidemiology of non-steroidal antiinflammatory drug use in Nottingham general practices. Aliment Pharmacol Ther 2000;14:177-85
12. Hawkey CJ, Cullen DJE, Pearson G, Holmes S, Doherty M, Wilson JV, et al. Ibuprofen versus other non-steroidal anti-inflammatory drugs: use in general practice and patient perception. Aliment Pharmacol Ther 2000;14:187-91
13. Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in treatment after start of new course of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995;311:293-5
14. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertension 1998;12(8):533-7
15. Langman M, Kahler KH, Kong SX, Zhang Q, Finch E, Bentkover JD, Stewart EJ. Drug switching among patients taking nonsteroidal anti-inflammatory drugs: retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Safety 2001;10:517-24
16. Singh G, Ramey DR. NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997. J Rheumatol 1998;25(Suppl 51):8-16
17. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Gastrointestinal health care resource use and costs associated with non-steroidal antiinflammatory drugs versus acetaminophen. Arthritis Rheum 2000;43:917-24
18. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-604
19. Singh G, Triadafilopoulos G. Epidemiology of NSAID-induced gastrointestinal complications. J Rheumatol 1999;26(Suppl 56):18-24
20. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72
21. Gabinete de Estudios Sociológicos Bernard Krief. Libro Blanco. Problemática de la gastroprotección frente a factores agresivos en España. Laboratorios Robert. NILO Industria Grágica S.A., Madrid: 1997
22. Silverstein FE, Graham DY, Senior JR Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9
23. Lanas A, Arroyo MT. Fármacos antisecretores y profilaxis de los efectos secundarios gastrointestinales graves asociad-os al consumo de antiinflamatorios no esteroides. Med Clin (Barc) 2000;114 (Suppl):57-62
24. Yeomans ND, Tulassy Z, Juhasz J, et al. for the Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:719-26
25. Hawkey CJ, Karrasch JA, Szczepanski L, et al. for the Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727-34
26. Gabriel S, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use on nonsteroidal antiinflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96
27. Scott DL, Shipley M, Dawson, Edwards S, Symmons DPM, Woolf D. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. Br J Rheumatol 1998:37:546-54
28. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2002;43:1905-15
29. Erviti J. Estudio multicéntrico prescripción-indicación de antiácidos y antiulcerosos en atención primaria. Aten Primaria 1999;24:134-9
30. Bakowsky VS, Hanly JG. Complications of nonsteroidal antiinflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary health care center. J Rheumatol 1999;26:1557-63
31. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
32. Watson DJ, Harper SE, Zhao PL, Hui Q, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160:2998-3003
33. Laine L, Bombardier C, Ramey DR, Watson DJ, Pellissier JM, Reicin A. Less use of gastrointestinal (GI) protective agents and GI-related procedures with rofecoxib vs. naproxen in the VIGOR (VIOXX GI outcomes Research) Study. Ann Rheum Dis 2001;60 (Suppl 1):278